BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Walker, P.G.T.; Whittaker, C.; Watson, O.J.; Baguelin, M.; Winskill, P.; Hamlet, A.; Djafaara, B.A.; Cucunubá, Z.; Mesa, D.O.; Green, W.; et al. The Impact of COVID-19 and Strategies for Mitigation and Suppression in Low- And Middle-Income Countries. Science 2020, 369, 413–422. [Google Scholar] [CrossRef]
- Zhang, Y.; Zeng, G.; Pan, H.; Li, C.; Hu, Y.; Chu, K.; Han, W.; Chen, Z.; Tang, R.; Yin, W.; et al. Safety, Tolerability, and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine in Healthy Adults Aged 18–59 Years: A Randomised, Double-Blind, Placebo-Controlled, Phase 1/2 Clinical Trial. Lancet Infect. Dis. 2021, 21, 181–192. [Google Scholar] [CrossRef] [PubMed]
- World Health Organization (WHO). Weekly Epidemiological Update on COVID-19 - 25 January 2023. Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---25-january-2023 (accessed on 26 January 2023).
- Italy: WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data|WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. Available online: https://covid19.who.int/region/euro/country/it (accessed on 28 January 2023).
- Istituto Superiore di Sanità (ISS) e Istituto Nazionale di Statistica (ISTAT). «IMPATTO DELL’EPIDEMIA COVID-19 SULLA MORTALITÀ TOTALE DELLA POPOLAZIONE RESIDENTE. ANNI 2020-2021 E GENNAIO 2022», Technical Report. 2022. Available online: https://www.istat.it/it/files//2022/03/Report_ISS_ISTAT_2022_tab3.pdf (accessed on 28 January 2023).
- Sacco, C.; Mateo-Urdiales, A.; Rota, M.C.; Fabiani, M.; Boros, S.; Bressi, M.; Fenicia Vescio, M.; Siddu, A.; Battilomo, S.; Del Manso, M..; et al. Infezioni Da SARS-CoV-2, Ricoveri e Decessi Associati a COVID-19 Direttamente Evitati Dalla Vaccinazione Italia, 27 Dicembre 2020-31 Gennaio 2022. Technical report. 2022. Available online: https://www.iss.it/documents/20126/6703853/NT_Eventi+evitati+COVID19_LAST.pdf/a140e155-bd62-adcd-1b29-d1be3464ed48?t=1649832260103 (accessed on 28 January 2023).
- Wilder-Smith, A.; Chiew, C.J.; Lee, V.J. Can We Contain the COVID-19 Outbreak with the Same Measures as for SARS? Lancet Infect. Dis. 2020, 20, e102–e107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ripabelli, G.; Tamburro, M.; Buccieri, N.; Adesso, C.; Caggiano, V.; Cannizzaro, F.; di Palma, M.A.; Mantuano, G.; Montemitro, V.G.; Natale, A.; et al. Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study. J. Community Health 2022, 47, 211–225. [Google Scholar] [CrossRef]
- Haque, A.; Pant, A.B. Efforts at COVID-19 Vaccine Development: Challenges and Successes. Vaccines 2020, 8, 739. [Google Scholar] [CrossRef] [PubMed]
- Kim, K.-D.; Hwang, I.; Ku, K.B.; Lee, S.; Kim, S.-J.; Kim, C. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses. J. Microbiol. Biotechnol. 2020, 30, 1109–1115. [Google Scholar] [CrossRef] [PubMed]
- Li, L.; Guo, P.; Zhang, X.; Yu, Z.; Zhang, W.; Sun, H. SARS-CoV-2 Vaccine Candidates in Rapid Development. Hum. Vaccines Immunother. 2020, 17, 644–653. [Google Scholar] [CrossRef]
- Ferrara, P.; Albano, L. COVID-19 and Healthcare Systems: What Should We Do Next? Public Health 2020, 185, 1. [Google Scholar] [CrossRef]
- Della Valle, P.; Fabbri, M.; Madotto, F.; Ferrara, P.; Cozzolino, P.; Calabretto, E.; D’orso, M.I.; Longhi, E.; Polosa, R.; Riva, M.A.; et al. Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG–OCCUPATION–COVID-19 Study. Int. J. Environ. Res. Public Health 2021, 18, 2567. [Google Scholar] [CrossRef]
- Ponticelli, D.; Madotto, F.; Conti, S.; Antonazzo, I.C.; Vitale, A.; della Ragione, G.; Romano, M.L.; Borrelli, M.; Schiavone, B.; Polosa, R.; et al. Response to BNT162b2 MRNA COVID-19 Vaccine among Healthcare Workers in Italy: A 3-Month Follow-Up. Intern. Emerg. Med. 2022, 17, 481–486. [Google Scholar] [CrossRef]
- Shimabukuro, T.; Nair, N. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. JAMA 2021, 325, 780–781. [Google Scholar] [CrossRef]
- EMA Recommends First COVID-19 Vaccine for Authorisation in the EU | European Medicines Agency. Available online: https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu (accessed on 28 January 2023).
- BioNTech/Pfizer Vaccine Authorised Answers to Frequently Asked Questions on AIFA’s Website. Available online: https://www.aifa.gov.it/en/-/autorizzato-il-vaccino-biontech-pfizer (accessed on 28 January 2023).
- Ministero della Salute Decreto 2 Gennaio 2021—Adozione Piano Strategico per La Vaccinazione Anti-SARS-CoV-2/COVID-19. Available online: https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2021&codLeg=78657&parte=1%20&serie=null (accessed on 28 January 2023).
- Dooling, K.; McClung, N.; Chamberland, M.; Marin, M.; Wallace, M.; Bell, B.P.; Lee, G.M.; Talbot, H.K.; Romero, J.R.; Oliver, S.E. The Advisory Committee on Immunization Practices’ Interim Recommendation for Allocating Initial Supplies of COVID-19 Vaccine—United States, 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 1857–1859. [Google Scholar] [CrossRef]
- Amit, S.; Beni, S.A.; Biber, A.; Grinberg, A.; Leshem, E.; Regev-Yochay, G. Postvaccination COVID-19 among Healthcare Workers, Israel—Volume 27, Number 4—April 2021—Emerging Infectious Diseases Journal—CDC. Emerg. Infect. Dis. 2021, 27, 1220–1222. [Google Scholar] [CrossRef] [PubMed]
- Ministero della Salute; Presidenza del Consiglio dei Ministri; Istituto Superiore di Sanità; Agenzia Nazionale per i Servizi Sanitari Regionali Vaccinazione Anti-SARS-CoV-2/COVID-19. Piano Strategico. Elementi Di Preparazione e Di Implementazione Della Strategia Vaccinale. Aggiornamento Del 12 Dicembre 2020. Gazzetta Ufficiale Della Repubblica Italiana Serie Generale—N. 72 Del 24-3-2021. Available online: https://www.trovanorme.salute.gov.it/norme/renderPdf.spring?seriegu=SG&datagu=24/03/2021&redaz=21A01802&artp=1&art=1&subart=1&subart1=10&vers=1&prog=001 (accessed on 28 January 2023).
- Gazzetta Ufficiale della Repubblica Italiana DECRETO-LEGGE 24 Marzo 2022, n. 24 Disposizioni Urgenti per Il Superamento Delle Misure Di Contrasto Alla Diffusione Dell’epidemia Da COVID-19, in Conseguenza Della Cessazione Dello Stato Di Emergenza. (22G00034) (GU Serie Generale n.70 Del 24-03-2022). Available online: https://www.gazzettaufficiale.it/eli/id/2022/03/24/22G00034/sg (accessed on 28 January 2023).
- Riccardo, F.; Guzzetta, G.; Urdiales, A.M.; del Manso, M.; Andrianou, X.D.; Bella, A.; Pezzotti, P.; Carbone, S.; de Vito, T.; Maraglino, F.; et al. COVID-19 Response: Effectiveness of Weekly Rapid Risk Assessments, Italy. Bull. World Health Organ. 2022, 100, 161–167. [Google Scholar] [CrossRef]
- Nurchis, M.C.; Lontano, A.; Pascucci, D.; Sapienza, M.; Marziali, E.; Castrini, F.; Messina, R.; Regazzi, L.; Causio, F.A.; di Pilla, A.; et al. COVID-19 Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Cost–Benefit Analysis. Int. J. Environ. Res. Public Health 2022, 19, 7848. [Google Scholar] [CrossRef] [PubMed]
- Rief, W. Fear of Adverse Effects and COVID-19 Vaccine Hesitancy: Recommendations of the Treatment Expectation Expert Group. JAMA Health Forum 2021, 2, e210804. [Google Scholar] [CrossRef] [PubMed]
- Wong, C.K.H.; Lau, K.T.K.; Xiong, X.; Au, I.C.H.; Lai, F.T.T.; Wan, E.Y.F.; Chui, C.S.L.; Li, X.; Chan, E.W.Y.; Gao, L.; et al. Adverse Events of Special Interest and Mortality Following Vaccination with MRNA (BNT162b2) and Inactivated (CoronaVac) SARS-CoV-2 Vaccines in Hong Kong: A Retrospective Study. PLoS Med. 2022, 19, e1004018. [Google Scholar] [CrossRef] [PubMed]
- Mahapatra, S.; Nagpal, R.; Marya, C.M.; Taneja, P.; Kataria, S. Adverse Events Occurring Post-Covid-19 Vaccination among Healthcare Professionals—A Mixed Method Study. Int. Immunopharmacol. 2021, 100, 108136. [Google Scholar] [CrossRef] [PubMed]
- Welcome|Public Health Ontario. Available online: https://www.publichealthontario.ca/ (accessed on 28 January 2023).
- World Health Organization. Global Manual on Surveillance of Adverse Events Following Immunization, 2016 Update. 2014. Available online: https://apps.who.int/iris/handle/10665/206144 (accessed on 28 January 2023).
- Bhandari, B.; Rayamajhi, G.; Lamichhane, P.; Shenoy, A.K. Adverse Events Following Immunization with COVID-19 Vaccines: A Narrative Review. Biomed. Res. Int. 2022, 2022, 2911333. [Google Scholar] [CrossRef] [PubMed]
- Tozzi, A.E.; Gesualdo, F.; D’Ambrosio, A.; Pandolfi, E.; Agricola, E.; Lopalco, P. Can Digital Tools Be Used for Improving Immunization Programs? Front. Public Health 2016, 4, 36. [Google Scholar] [CrossRef]
- World Health Organization (WHO). Covid-19 Vaccines: Safety Surveillance Manual; World Health Organization: Geneva, Switzerland, 2020. [Google Scholar]
- Adverse Events Following Immunization (AEFI). Available online: https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance/health-professionals-info/aefi (accessed on 28 January 2023).
- Adverse Events Following Immunisation: What Are They, and When Are They Cause for Concern?|Gavi, the Vaccine Alliance. Available online: https://www.gavi.org/vaccineswork/adverse-events-following-immunisation-what-are-they-and-when-are-they-cause-concern (accessed on 28 January 2023).
- Turner, P.J.; Ansotegui, I.J.; Campbell, D.E.; Cardona, V.; Ebisawa, M.; El-Gamal, Y.; Fineman, S.; Geller, M.; Gonzalez-Estrada, A.; Greenberger, P.A.; et al. COVID-19 Vaccine-Associated Anaphylaxis: A Statement of the World Allergy Organization Anaphylaxis Committee. World Allergy Organ. J. 2021, 14, 100517. [Google Scholar] [CrossRef] [PubMed]
- Crawford, N.W.; Clothier, H.; Hodgson, K.; Selvaraj, G.; Easton, M.L.; Buttery, J.P. Active Surveillance for Adverse Events Following Immunization. Expert Rev. Vaccines 2014, 13, 265–276. [Google Scholar] [CrossRef] [PubMed]
- Cashman, P.; Macartney, K.; Khandaker, G.; King, C.; Gold, M.; Durrheima, D.N. Participant-Centred Active Surveillance of Adverse Events Following Immunisation: A Narrative Review. Int. Health 2017, 9, 164–176. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Heininger, U.; Holm, K.; Caplanusi, I.; Bailey, S.R.; Asfijah Abdoellah, S.; Arellano, F.; Arlett, P.; Ayoub, A.; Sjafri Bachtiar, N.; Bahri, P.; et al. Guide to Active Vaccine Safety Surveillance: Report of CIOMS Working Group on Vaccine Safety—Executive Summary. Vaccine 2017, 35, 3917–3921. [Google Scholar] [CrossRef] [PubMed]
- Waldman, E.A.; Luhm, K.R.; Monteiro, S.A.M.G.; Freitas, F.R.M. de Surveillance of Adverse Effects Following Vaccination and Safety of Immunization Programs. Rev. Saude Publica 2011, 45, 173–184. [Google Scholar] [CrossRef] [Green Version]
- Pharmacovigilance on COVID-19 Vaccines|Italian Medicines Agency. Available online: https://www.aifa.gov.it/en/farmacovigilanza-vaccini-covid-19 (accessed on 28 January 2023).
- Rosenblum, H.G.; Gee, J.; Liu, R.; Marquez, P.L.; Zhang, B.; Strid, P.; Abara, W.E.; McNeil, M.M.; Myers, T.R.; Hause, A.M.; et al. Safety of MRNA Vaccines Administered during the Initial 6 Months of the US COVID-19 Vaccination Programme: An Observational Study of Reports to the Vaccine Adverse Event Reporting System and v-Safe. Lancet Infect. Dis. 2022, 22, 802–812. [Google Scholar] [CrossRef]
- Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [Google Scholar] [CrossRef]
- Anderson, E.J.; Rouphael, N.G.; Widge, A.T.; Jackson, L.A.; Roberts, P.C.; Makhene, M.; Chappell, J.D.; Denison, M.R.; Stevens, L.J.; Pruijssers, A.J.; et al. Safety and Immunogenicity of SARS-CoV-2 MRNA-1273 Vaccine in Older Adults. N. Engl. J. Med. 2020, 383, 2427–2438. [Google Scholar] [CrossRef]
- Baden, L.R.; el Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.; Creech, C.B.; et al. Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021, 384, 403–416. [Google Scholar] [CrossRef]
- Barda, N.; Dagan, N.; Ben-Shlomo, Y.; Kepten, E.; Waxman, J.; Ohana, R.; Hernán, M.A.; Lipsitch, M.; Kohane, I.; Netzer, D.; et al. Safety of the BNT162b2 MRNA Covid-19 Vaccine in a Nationwide Setting. N. Engl. J. Med. 2021, 385, 1078–1090. [Google Scholar] [CrossRef]
- Klein, N.P.; Lewis, N.; Goddard, K.; Fireman, B.; Zerbo, O.; Hanson, K.E.; Donahue, J.G.; Kharbanda, E.O.; Naleway, A.; Nelson, J.C.; et al. Surveillance for Adverse Events after COVID-19 MRNA Vaccination. JAMA—J. Am. Med. Assoc. 2021, 326, 1390–1399. [Google Scholar] [CrossRef] [PubMed]
- García-Grimshaw, M.; Ceballos-Liceaga, S.E.; Hernández-Vanegas, L.E.; Núñez, I.; Hernández-Valdivia, N.; Carrillo-García, D.A.; Michel-Chávez, A.; Galnares-Olalde, J.A.; Carbajal-Sandoval, G.; del Mar Saniger-Alba, M.; et al. Neurologic Adverse Events among 704,003 First-Dose Recipients of the BNT162b2 MRNA COVID-19 Vaccine in Mexico: A Nationwide Descriptive Study. Clin. Immunol. 2021, 229, 108786. [Google Scholar] [CrossRef] [PubMed]
- Lai, F.T.T.; Li, X.; Peng, K.; Huang, L.; Ip, P.; Tong, X.; Chui, C.S.L.; Wan, E.Y.F.; Wong, C.K.H.; Chan, E.W.Y.; et al. Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine A Case-Control Study. Ann. Intern. Med. 2022, 175, 362–370. [Google Scholar] [CrossRef] [PubMed]
- Shemer, A.; Pras, E.; Einan-Lifshitz, A.; Dubinsky-Pertzov, B.; Hecht, I. Association of COVID-19 Vaccination and Facial Nerve Palsy: A Case-Control Study. JAMA Otolaryngol. Head Neck Surg. 2021, 147, 739–743. [Google Scholar] [CrossRef]
- Allegato, I. Riassunto delle Caratteristiche del Prodotto Comirnaty Original/Omicron BA.1, Summary of Product Characteristics. 2023. Available online: https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_005389_050306_RCP.pdf&retry=0&sys=m0b1l3 (accessed on 28 January 2023).
- McKenzie, E.; Zhang, L.; Zaki, P.; Chan, S.; Ganesh, V.; Razvi, Y.; Tsao, M.; Barnes, E.; Hwang, M.K.; Deangelis, C.; et al. Re-Analysis of Symptom Clusters in Advanced Cancer Patients Attending a Palliative Outpatient Radiotherapy Clinic. Ann. Palliat. Med 2019, 8, 140–149. [Google Scholar] [CrossRef]
- Ye, W.; Lu, W.; Tang, Y.; Chen, G.; Li, X.; Ji, C.; Hou, M.; Zeng, G.; Lan, X.; Wang, Y.; et al. Identification of COVID-19 Clinical Phenotypes by Principal Component Analysis-Based Cluster Analysis. Front. Med. 2020, 7, 782. [Google Scholar] [CrossRef]
- Agenzia Italiana del Farmaco (AIFA). Rapporto Sulla Sorveglianza Dei Vaccini Anti-COVID-19 13 27/12/2020—26/09/2022. Technical report. 2022. Available online: https://www.aifa.gov.it/documents/20142/1315190/Rapporto_sorveglianza_vaccini_COVID-19_13.pdf (accessed on 28 January 2023).
- Pascucci, D.; Nurchis, M.C.; Sapienza, M.; Castrini, F.; Beccia, F.; D’ambrosio, F.; Grossi, A.; Castagna, C.; Pezzullo, A.M.; Zega, M.; et al. Evaluation of the Effectiveness and Safety of the Bnt162b2 Covid-19 Vaccine in the Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli Irccs. Int. J. Environ. Res. Public Health 2021, 18, 11098. [Google Scholar] [CrossRef]
- Gringeri, M.; Mosini, G.; Battini, V.; Cammarata, G.; Guarnieri, G.; Carnovale, C.; Clementi, E.; Radice, S. Preliminary Evidence on the Safety Profile of BNT162b2 (Comirnaty): New Insights from Data Analysis in EudraVigilance and Adverse Reaction Reports from an Italian Health Facility. Hum. Vaccin. Immunother. 2021, 17, 2969. [Google Scholar] [CrossRef]
- Pietro Vigezzi, G.; Lume, A.; Minerva, M.; Nizzero, P.; Biancardi, A.; Gianfredi, V.; Odone, A.; Signorelli, C.; Moro, M. Safety Surveillance after BNT162b2 MRNA COVID-19 Vaccination: Results from a Cross-Sectional Survey among Staff of a Large Italian Teaching Hospital. Acta Biomed. 2021, 92, e2021450. [Google Scholar] [CrossRef]
- Ughi, N.; del Gaudio, F.; Dicuonzo, A.; Orso, M.; Micheloni, G.; Puoti, M.; Pani, A.; Scaglione, F.; Zoppini, L.; Rossetti, C.; et al. Host Factors and History of SARS-CoV-2 Infection Impact the Reactogenicity of BNT162b2 MRNA Vaccine: Results from a Cross-Sectional Survey on 7,014 Workers in Healthcare. Eur. Rev. Med. Pharmacol. Sci. 2021, 25, 7985–7996. [Google Scholar] [CrossRef]
- Borroni, E.; Consonni, D.; Cugno, M.; Lombardi, A.; Mangioni, D.; Bono, P.; Oggioni, M.; Renteria, S.U.; Bordini, L.; Nava, C.D.; et al. Side Effects among Healthcare Workers from a Large Milan University Hospital after Second Dose of Bnt162b2mrna Covid-19 Vaccine. Medicina del Lavoro 2021, 112, 477–485. [Google Scholar] [CrossRef] [PubMed]
- Alomar, M.; Palaian, S.; Al-Tabakha, M.M. Open Peer Review Pharmacovigilance in Perspective: Drug Withdrawals, Data Mining and Policy Implications [Version 1; Peer Review: 2 Approved]. F1000Research 2019, 8, 2019. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Carnovale, C.; Gringeri, M.; Battini, V.; Mosini, G.; Invernizzi, E.; Mazhar, F.; Bergamaschi, F.; Fumagalli, M.; Zuccotti, G.; Clementi, E.; et al. Beta-Blocker-Associated Hypoglycaemia: New Insights from a Real-World Pharmacovigilance Study. Br. J. Clin. Pharmacol. 2021, 87, 3320–3331. [Google Scholar] [CrossRef]
- Aristei, L.; D’ambrosio, F.; Villani, L.; Rossi, M.F.; Daniele, A.; Amantea, C.; Damiani, G.; Laurenti, P.; Ricciardi, W.; Gualano, M.R.; et al. Public Health Regulations and Policies Dealing with Preparedness and Emergency Management: The Experience of the COVID-19 Pandemic in Italy. Int. J. Environ. Res. Public Health 2022, 19, 1091. [Google Scholar] [CrossRef] [PubMed]
- Araja, D.; Krumina, A.; Nora-Krukle, Z.; Berkis, U.; Murovska, M. Vaccine Vigilance System: Considerations on the Effectiveness of Vigilance Data Use in COVID-19 Vaccination. Vaccines 2022, 10, 2115. [Google Scholar] [CrossRef]
- Guo, Q.; Duan, S.; Liu, Y.; Yuan, Y. Adverse Drug Events in the Prevention and Treatment of COVID-19: A Data Mining Study on the FDA Adverse Event Reporting System. Front. Pharmacol. 2022, 13, 954359. [Google Scholar] [CrossRef]
- Beccia, F.; di Pilla, A.; Causio, F.A.; Federico, B.; Specchia, M.L.; Favaretti, C.; Boccia, S.; Damiani, G. Narrative Review of the COVID-19 Pandemic’s First Two Years in Italy. Int. J. Environ. Res. Public Health 2022, 19, 15443. [Google Scholar] [CrossRef]
System Organ Class | Very Common (≥1/10) | Common (≥1/100 to <1/10) | Uncommon (≥1/1000 to <1/100) | Rare (≥1/10,000 to <1/1000) | Very Rare (<1/10,000) | Not Known § |
---|---|---|---|---|---|---|
Blood and lymphatic system disorders | – | – | Lymphadenopathy 9.10% | – | – | – |
Immune system disorders | – | – | Hypersensitivity reactions (e.g., rash, pruritus,) 6.71% | Hypersensitivity reactions (urticaria, angioedema) NR | – | Anaphylaxis NR |
Metabolism and nutrition disorders | – | – | Decreased appetite NR | – | – | – |
Psychiatric disorders | – | – | Insomnia 20.06% | – | – | – |
Nervous system disorders | Headache 27.68% (ref. >50%) | – | Lethargy NR | Acute peripheral facial paralysis NR Photophobia 0.08% Presyncope 0.04% | – | Paresthesia 0.25% Hypoaesthesia 0.04% |
Cardiac disorders | Tachycardia 0.12% (ref. >60%) | – | – | Myocarditis; Pericarditis NR | ||
Respiratory disorders * | – | – | – | Sinus congestion 0.08% Cough 0.08% | – | – |
Gastrointestinal disorders | Diarrhea 0.21% | Nausea 13.96% Vomiting 0.04% | Gastrointestinal disorders 0.12% | – | – | – |
Skin and subcutaneous tissue disorder | Hyperhidrosis 0.08% Night sweats 0.12% | Aphtha 0.04% | – | Eritema multiforme NR | ||
Musculoskeletal and connective tissue disorders | Arthralgia 0.12% (ref. >20%) Myalgia 0.04% (ref. >40%) Localized pain 36.90% | – | Pain in extremity NR | – | – | – |
General disorders and administration site conditions | Injection site pain 63.92% (ref. >80%) Fatigue 48.23% (ref. >60%) Chills 21.29% (ref. >30%) Pyrexia 16.89 (ref. >10%) Injection site swelling 0.04% (ref.>10%) | Injection site redness 0.04% | Malaise 37.77% Injection site pruritus NR Asthenia 0.12% | Pustule 0.04% | – | Extensive swelling of vaccinated limb NR Facial swelling NR |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Beccia, F.; Regazzi, L.; Marziali, E.; Beccia, V.; Pascucci, D.; Mores, N.; Vetrugno, G.; Laurenti, P. BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy. Vaccines 2023, 11, 477. https://doi.org/10.3390/vaccines11020477
Beccia F, Regazzi L, Marziali E, Beccia V, Pascucci D, Mores N, Vetrugno G, Laurenti P. BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy. Vaccines. 2023; 11(2):477. https://doi.org/10.3390/vaccines11020477
Chicago/Turabian StyleBeccia, Flavia, Luca Regazzi, Eleonora Marziali, Viria Beccia, Domenico Pascucci, Nadia Mores, Giuseppe Vetrugno, and Patrizia Laurenti. 2023. "BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy" Vaccines 11, no. 2: 477. https://doi.org/10.3390/vaccines11020477
APA StyleBeccia, F., Regazzi, L., Marziali, E., Beccia, V., Pascucci, D., Mores, N., Vetrugno, G., & Laurenti, P. (2023). BNT162b2 COVID-19 Vaccine Safety among Healthcare Workers of a Tertiary Hospital in Italy. Vaccines, 11(2), 477. https://doi.org/10.3390/vaccines11020477